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In this issue of the Journal of Thoracic Oncology, Litvak et al.1 describe the clinical char-acteristics and course of a cohort of 63 BRAF-mutated Non–Small-Cell Lung Cancers 
diagnosed in a single center between 2009 and 2013. BRAF mutations, notably the V600E 
mutation, have been described in a number of malignancies, among others melanoma, 
colon cancer, and thyroid cancer, and is both a bona fide oncogenic driver and predictive for 
response to single agent vemurafenib and dabrafenib. V600E BRAF-mutated non–small-
cell lung cancer (NSCLC) is no exception to the latter as numerous case studies describe 
major and durable responses to these agents in the second and further line settings.2,3 
Moreover, an interim analysis of a phase II study testing single agent dabrafenib in V600E 
BRAF-mutated NSCLC reported at the annual ASCO meeting in 2012, showed a 60% dis-
ease control rate and an objective response rate of 40%.4 Much less is known in this respect 
of non-V600E BRAF mutations which constitute approximately 50% of BRAF mutations in 
lung cancer. Although V600E BRAF mutations result in tumor development through their 
intrinsic ability to hyperactivate the MEK-ERK pathway,5 non-V600E BRAF mutations 
induce this pathway at lower levels and are significantly coincident with KRAS mutations 
in human cancer specimen, the latter which may be required for malignant transformation.6 
The clinical significance of non-V600E BRAF mutations remains to be elucidated. Some, 
such as the inactivating D594G mutation are resistant to vemurafenib but sensitive to dasat-
inib7 and a clinical trial testing this hypothesis is underway (NCT01514864).
Although the report represents the largest series as of today, clearly the number of 
patients included cautions against firm conclusions. Nevertheless, several of the findings 
are worth noticing. First, the incidence of BRAF mutation was not reported. A recent meta-
analysis8 and data from a large cohort from France9 suggest that in adenocarcinoma the 
incidene is approximately 2%. In contrast to the memorial series, where it was explicitly 
stated that all adenocarcinoma patients were tested for the mutation, in both former series it 
is not clear if and how patients were selected for genetic testing. For two reasons this may 
be important: the occurrence of BRAF mutations in squamous cell cancers,10 albeit in lower 
frequencies and the fact that these mutations are present in tumors regardless the smoking 
status of the patient. Admittedly, in keeping with previous reports, the incidence of V600E 
BRAF mutations was somewhat higher in never or light smokers, but a significant number 
was detected in heavy smokers. Along with the notion that other actionable genetic abnor-
malities (EGFR mutations and Alk rearrangements) in lung cancer may occur outside the 
classical phenotype consisting of the triad women, nonsmoking, and adenocarcinoma,11 
this finding lends credit to the position that genetic testing should be considered in all 
advanced NSCLC patients regardless their phenotype.
Given the fact that V600E BRAF mutations convey predictive information it is of 
academic interest whether these also have prognostic features. Previous reports from surgi-
cal series suggest that indeed V600E but not non-V600E BRAF mutations convey a worse 
prognosis as compared with wild type BRAF NSCLC.12 In the subset of early stage patients 
(n = 29) reported by Litvak,1 survival was similar between V600E and non-V600E patients 
and not different from KRAS and EGFR-mutated early stage patients. In advanced patients, 
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there was no difference in survival between BRAF-mutated 
and either KRAS-mutated or EGFR-mutated patients but this 
analysis is hampered by the fact that half the BRAF-mutated 
patients and all EGFR-mutated patients received targeted thera-
pies according to their mutation. Another large series reported 
by Cardarella et al.13 found no difference in progression-free 
and overall survival between 336 BRAF mutated and wild type 
tumours when treated with platinum-based chemotherapy. Thus, 
the jury is still out whether BRAF mutations carry prognostic 
information and if so, in the advanced setting this is probably 
limited. The implication here is that currently there is no need 
for stratification in clinical trials based upon BRAF mutation 
status, in contrast to EGFR mutations or Alk rearrangements.
Perhaps the most interesting finding in the series reported 
by Latvik is the observation that in secondary lung cancers 
approximately 20% harbored a KRAS mutation and one patient 
had an activating EGFR mutation. Whether in these tumours 
the identical BRAF mutation was detected as in the index lung 
malignancy is not stated in the manuscript. Of particular interest, 
four of six harbored non-V600E BRAF mutations. Likewise, no 
data on other genomic features, for instance array-comparative 
gemonic hybridization to further differentiate between metas-
tasis or second primaries, were presented. This information 
would have been helpful given the heterogeneity in the distribu-
tion of genomic alterations in (lung) cancer. Although reported 
infrequently, BRAF mutations do occur in concert with other 
activating mutations, in particular EGFR and KRAS mutations. 
This finding may have implications for the development of 
resistance to BRAF inhibitors in advanced disease: a case report 
published in this journal by rudin et al14 found a KRAS muta-
tion in a BRAF-mutated tumor upon progression on treatment 
with vemurafenib. Others found evidence of EGFr-driven 
resistance in clinical samples of patients resistant to treatment 
with BRAF inhibitors.15 The observation that second lung pri-
maries reported by Litvak et al1 may contain KRAS and EGFR 
mutations may therefore have implications for the management 
of advanced BRAF-mutated lung cancer patients and calls for 
detailed molecular analysis of relapse tumor samples.
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